A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Myasthenia Gravis

Interventions

DRUG: CC-97540
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

[object Object]